ECSP034642A - Derivados de tetralona como agentes antitumorales - Google Patents

Derivados de tetralona como agentes antitumorales

Info

Publication number
ECSP034642A
ECSP034642A EC2003004642A ECSP034642A ECSP034642A EC SP034642 A ECSP034642 A EC SP034642A EC 2003004642 A EC2003004642 A EC 2003004642A EC SP034642 A ECSP034642 A EC SP034642A EC SP034642 A ECSP034642 A EC SP034642A
Authority
EC
Ecuador
Prior art keywords
tetralona
derivatives
antitumor agents
compounds
cancer
Prior art date
Application number
EC2003004642A
Other languages
English (en)
Inventor
Adelbert Grossmann
Guy Georges
Tim Sattelkau
Wolfgang Schaefer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP034642A publication Critical patent/ECSP034642A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Los compuestos de la siguiente fórmula: (gráfico) en la cual R1,R2,R3,R4,R5, X e Y, tienen los significados mencionados en la memoria descriptiva, proceso para la manufactura de estos compuestos y composiciones farmacéuticas que contienen un compuesto de este tipo, presentan una actividad inhibidora de la HDAC, y son útiles en el tratamiento del cáncer
EC2003004642A 2000-12-07 2003-06-05 Derivados de tetralona como agentes antitumorales ECSP034642A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00126820 2000-12-07

Publications (1)

Publication Number Publication Date
ECSP034642A true ECSP034642A (es) 2003-07-25

Family

ID=8170594

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004642A ECSP034642A (es) 2000-12-07 2003-06-05 Derivados de tetralona como agentes antitumorales

Country Status (26)

Country Link
US (1) US6531472B2 (es)
EP (1) EP1349830A1 (es)
JP (1) JP4091431B2 (es)
KR (1) KR20030077551A (es)
CN (1) CN100340545C (es)
AR (1) AR035659A1 (es)
AU (2) AU1607402A (es)
BG (1) BG107889A (es)
BR (1) BR0115988A (es)
CA (1) CA2430355A1 (es)
CZ (1) CZ20031833A3 (es)
EC (1) ECSP034642A (es)
HK (1) HK1060875A1 (es)
HR (1) HRP20030451A2 (es)
HU (1) HUP0400579A2 (es)
IL (1) IL156133A0 (es)
MA (1) MA26972A1 (es)
MX (1) MXPA03004947A (es)
NO (1) NO20032531L (es)
NZ (1) NZ526051A (es)
PL (1) PL365324A1 (es)
RU (1) RU2288220C2 (es)
SK (1) SK8512003A3 (es)
WO (1) WO2002046144A1 (es)
YU (1) YU45803A (es)
ZA (1) ZA200304262B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
EP2269609A3 (en) * 2001-10-16 2012-07-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases and cancer of the brain with SAHA
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
RU2320331C2 (ru) 2002-03-04 2008-03-27 МЕРК ЭйчДиЭйСи Рисерч, ЛЛС. Способ индукции конечной дифференцировки
AU2003226014A1 (en) * 2002-03-28 2003-10-13 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
CA2481466A1 (en) * 2002-04-05 2003-10-16 Yoshinori Naoe Depsipeptide for therapy of kidney cancer
US20040018968A1 (en) * 2002-04-15 2004-01-29 George Sgouros Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2003288433B2 (en) * 2002-12-05 2009-06-25 Imperial College Innovations Limited Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
JP2006520796A (ja) * 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
ATE462426T1 (de) 2003-08-26 2010-04-15 Merck Hdac Res Llc Verwendung von saha zur behandlung von mesotheliom
CN102349927A (zh) 2003-08-29 2012-02-15 Hdac默克研究有限责任公司 联合治疗癌症的方法
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
EP1734999A2 (en) * 2004-04-05 2006-12-27 Myogen, Inc. Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
WO2005099747A1 (en) * 2004-04-14 2005-10-27 Medical Research Council Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
KR100632800B1 (ko) 2004-10-21 2006-10-16 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 신규한하이드록시아마이드 유도체 및 이의 제조 방법
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006122319A2 (en) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
WO2007011626A2 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2015051035A1 (en) 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
EP3769757A3 (en) * 2013-10-18 2021-10-06 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
WO2020205455A1 (en) * 2019-03-29 2020-10-08 Taiwanj Pharmaceuticals, Co., Ltd. Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448730A (en) * 1981-03-24 1984-05-15 Riet Bartholomeus Van T Hydroxybenzohydroxamic acids, benzamides and esters and related compounds as ribonucleotide reductase inhibitors
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5637946A (en) * 1993-10-28 1997-06-10 Lockheed Corporation Thermally energized electrical power source
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds

Also Published As

Publication number Publication date
BG107889A (bg) 2004-06-30
US20020065282A1 (en) 2002-05-30
US6531472B2 (en) 2003-03-11
IL156133A0 (en) 2003-12-23
PL365324A1 (en) 2004-12-27
CN1478072A (zh) 2004-02-25
AU1607402A (en) 2002-06-18
SK8512003A3 (en) 2004-04-06
WO2002046144A1 (en) 2002-06-13
HK1060875A1 (en) 2004-08-27
CZ20031833A3 (cs) 2004-02-18
NO20032531D0 (no) 2003-06-04
MA26972A1 (fr) 2004-12-20
RU2288220C2 (ru) 2006-11-27
JP2004515488A (ja) 2004-05-27
EP1349830A1 (en) 2003-10-08
YU45803A (sh) 2006-05-25
AR035659A1 (es) 2004-06-23
MXPA03004947A (es) 2003-09-10
NZ526051A (en) 2004-12-24
ZA200304262B (en) 2004-08-30
NO20032531L (no) 2003-06-04
BR0115988A (pt) 2004-01-13
HRP20030451A2 (en) 2005-04-30
JP4091431B2 (ja) 2008-05-28
AU2002216074C1 (en) 2006-12-07
CA2430355A1 (en) 2002-06-13
KR20030077551A (ko) 2003-10-01
CN100340545C (zh) 2007-10-03
AU2002216074B2 (en) 2006-01-05
HUP0400579A2 (hu) 2004-06-28

Similar Documents

Publication Publication Date Title
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
ATE433447T1 (de) Pyrimiidinverbindungen
UY28572A1 (es) Compuestos novedosos
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PA8631201A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida
ECSP055867A (es) Derivados de pirrolopirimidina
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
ECSP045073A (es) Nuevos derivados de piperazina
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
ECSP066966A (es) Compuestos de aril-o heteroarilamida ortosustituidos
CR7877A (es) Derivados de 4-tetrazolil-4-fenilpiperidina para tratar el dolor
ECSP099371A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
ATE538124T1 (de) Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
ECSP088484A (es) Derivados de quinazolina espirocíclicos como inhibidores de pde7
PA8632601A1 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
CR10974A (es) Inhibidores de carboxipeptidasa b plasmatica (divisional)
UY30397A1 (es) Derivados sustituidos de la (3as, 7as)-1,3a,4,5,6,7-hexahidro-3h-benzoimidazol-2-ona, proceso de preparacion, composiciones conteniéndolos yaplicaciones
BR0208017A (pt) Combinação compreendendo combretastatina e agentes anticâncer
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
UY28486A1 (es) Compuestos quimicos